Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dp001. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 6/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dp001 SCHEMBL12961887 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL19988220 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL29645040 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL15371114 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL15371106 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL18470321 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL8303273 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL10307542 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL21206294 | 1.00 | VDR (0.81) | VDR | |
| Dp001 SCHEMBL12332637 | 1.00 | VDR (0.81) | VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122053192-A | Knowledge graph construction method and device for network security operation behavior | 关保网络安全技术(广东)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260094111-A1 | WORK MACHINE, AND PORTABLE TERMINAL DEVICE FOR WORK MACHINE | SUMITOMO CONSTRUCTION MACHINERY CO LTD (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12503454-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-10-02 | — | — | US | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| CN-119623004-A | New energy station digital transformation propulsion method | 广东省能源集团贵州有限公司华中分公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20240408037-A1 | PARENTERAL CANNABINOID FORMULATIONS AND USES THEREOF | Isosceles Pharmaceuticals, Inc. (US) | 2024-12-12 | — | — | US | disclosed |
| US-20170326159-A1 | METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID | WISCONSIN ALUMNI RES FOUND (US) | 2017-11-16 | — | — | US | disclosed |
| US-20160089385-A1 | VITAMIN D RECEPTOR AGONISTS TO TREAT DISEASES INVOLVING CXCL12 ACTIVITY | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160089385-A1 | VITAMIN D RECEPTOR AGONISTS TO TREAT DISEASES INVOLVING CXCL12 ACTIVITY | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-03-31 | — | — | US | disclosed |
| US-8318708-B2 | Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110014126-A1 | USE OF VITAMIN D RECEPTOR AGONISTS AND PRECURSORS TO TREAT FIBROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-20 | — | — | US | disclosed |
| US-20100160267-A1 | Treatment of Inflammatory Bowel Disease With 2-Methylene-19-Nor-Vitamin D Compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160267-A1 | Treatment of Inflammatory Bowel Disease With 2-Methylene-19-Nor-Vitamin D Compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-7704980-B2 | ulcerative colitis and Crohn's disease; 1 alpha -hydroxy-2-methylene-19-nor-homopregnacalciferol or 2-methylene-19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-04-27 | — | — | US | disclosed |
| US-7704980-B2 | ulcerative colitis and Crohn's disease; 1 alpha -hydroxy-2-methylene-19-nor-homopregnacalciferol or 2-methylene-19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090209500-A1 | USE OF VITAMIN D RECEPTOR AGONISTS AND PRECURSORS TO TREAT FIBROSIS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326159-A1 | METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID | CYP24A1, CYP2R1, VDR | VDR 3/4885 |
| US-20160089385-A1 | VITAMIN D RECEPTOR AGONISTS TO TREAT DISEASES INVOLVING CXCL12 ACTIVITY | GLP1R, VDR, CXCL12 | VDR 2/4885 |
| US-20260094111-A1 | WORK MACHINE, AND PORTABLE TERMINAL DEVICE FOR WORK MACHINE | WAPL, STRAP, PARP8 | VDR 2602/4885 |
| US-20100160267-A1 | Treatment of Inflammatory Bowel Disease With 2-Methylene-19-Nor-Vitamin D Compounds | CYP24A1, CYP2R1, VDR | VDR 3/4885 |
| US-20110014126-A1 | USE OF VITAMIN D RECEPTOR AGONISTS AND PRECURSORS TO TREAT FIBROSIS | VDR, CYP2R1, CYP24A1 | VDR 1/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | VDR 2582/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | VDR 2395/4885 |
| US-12503454-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | VDR 475/4885 |
| US-20090209500-A1 | USE OF VITAMIN D RECEPTOR AGONISTS AND PRECURSORS TO TREAT FIBROSIS | VDR, CYP24A1, CYP2R1 | VDR 1/4885 |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | VDR 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.